Related Experiment Videos
Decreased numbers of platelet alpha-adrenergic binding sites in diabetes mellitus
Insights
Diabetic men have fewer platelet alpha-adrenergic binding sites compared to controls. These reduced sites correlate with higher glycosylated hemoglobin levels, indicating a link between diabetes control and platelet receptor density.
Area of Science:
- Endocrinology
- Cardiovascular Research
- Platelet Physiology
Background:
- Platelet alpha-adrenergic receptors play a role in hemostasis and cardiovascular regulation.
- Alterations in platelet function are observed in diabetes mellitus.
- Understanding these changes may offer insights into diabetic complications.
Purpose of the Study:
- To investigate potential differences in platelet alpha-adrenergic binding sites between men with diabetes mellitus and healthy male controls.
- To explore the relationship between the number of these binding sites and glycemic control indicators.
Main Methods:
- Utilized [3H]dihydroergocryptine (DHE) as a radioligand antagonist to quantify platelet alpha-adrenergic binding sites.
- Compared binding affinity and site density between 11 diabetic men and 45 male controls.
- Assessed correlations with glycosylated hemoglobin, catecholamine levels, disease duration, body weight, and fasting blood sugar.
Main Results:
- No significant difference in binding affinity was found between diabetic subjects and controls.
- Diabetic men exhibited a significantly lower number of platelet alpha-adrenergic binding sites (430 +/- 30) compared to controls (574 +/- 29; P = .005).
- The reduction in binding sites was inversely correlated with elevated glycosylated hemoglobin levels (P = .002), but not with other clinical parameters.
Conclusions:
- Men with diabetes mellitus demonstrate a reduced density of platelet alpha-adrenergic binding sites.
- This reduction is significantly associated with poorer glycemic control, as indicated by higher glycosylated hemoglobin levels.
- Further research is warranted to elucidate the pathophysiological implications of these findings in diabetes.
Abstract:
Eleven men with diabetes mellitus were compared with 45 male controls for platelet alpha-adrenergic binding sites by using [3H]dihydroergocryptine (DHE) as the radioligand antagonist. There was no difference between the two for binding affinity, but the number of sites was 430 +/- 30 (means +/- SEM) for diabetic subjects and 574 +/- 29 for controls (P = .005). Decreased sites were related to increased glycosylated hemoglobin levels (P = .002). There was no relationship between the decreased sites and catecholamine levels, duration of disease, body weight, or fasting blood sugar. Hence, binding sites were inversely related to control, but further studies are needed to define the pathophysiologic significance of this.